Patient
SITE004-0220
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2026-05-22
Adverse events
1
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 1
moderate
assessed
2026-07-04
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 31); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.